ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Targeted Alpha-particle Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-21X17111
Home | Market Reports | Health| Health Conditions| Cancer
Global Targeted Alpha particle Therapy Market Research Report 2024
BUY CHAPTERS

Global Targeted Alpha-particle Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-21X17111
Report
November 2025
Pages:122
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bayer
Orano Med
Perspective Therapeutics
Oncoinvent AS
Ablaze Pharma
ARTBIO
Fusion Pharmaceuticals(AstraZeneca)
AlphaGen Therapeutics

Targeted Alpha-particle Therapy Market

The global Targeted Alpha-particle Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. It has the potential to provide highly targeted treatment, especially to microscopic tumour cells. Targets include leukemias, lymphomas, gliomas, melanoma, and peritoneal carcinomatosis. As in diagnostic nuclear medicine, appropriate radionuclides can be chemically bound to a targeting biomolecule which carries the combined radiopharmaceutical to a specific treatment point.
From a downstream perspective, Immunotherapy accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Targeted Alpha-particle Therapy leading manufacturers including Bayer, Orano Med, Oncoinvent AS, Perspective Therapeutics, Ablaze Pharma, ARTBIO, Fusion Pharmaceuticals(AstraZeneca), AlphaGen Therapeutics, etc., dominate supply; the top five capture approximately % of global revenue, with Bayer leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Targeted Alpha-particle Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Targeted Alpha-particle Therapy Market Report

Report Metric Details
Report Name Targeted Alpha-particle Therapy Market
Segment by Type
  • Actinium-225
  • Astatine-211
  • Lead-212
  • Bismuth-213
  • Others
Segment by Application
  • Immunotherapy
  • Peritoneal Carcinomas
  • Bone Metastases
  • Leukaemia
  • Melanomas
  • Solid Tumours
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bayer, Orano Med, Oncoinvent AS, Perspective Therapeutics, Ablaze Pharma, ARTBIO, Fusion Pharmaceuticals(AstraZeneca), AlphaGen Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Targeted Alpha-particle Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Targeted Alpha-particle Therapy Market report?

Ans: The main players in the Targeted Alpha-particle Therapy Market are Bayer, Orano Med, Oncoinvent AS, Perspective Therapeutics, Ablaze Pharma, ARTBIO, Fusion Pharmaceuticals(AstraZeneca), AlphaGen Therapeutics

What are the Application segmentation covered in the Targeted Alpha-particle Therapy Market report?

Ans: The Applications covered in the Targeted Alpha-particle Therapy Market report are Immunotherapy, Peritoneal Carcinomas, Bone Metastases, Leukaemia, Melanomas, Solid Tumours

What are the Type segmentation covered in the Targeted Alpha-particle Therapy Market report?

Ans: The Types covered in the Targeted Alpha-particle Therapy Market report are Actinium-225, Astatine-211, Lead-212, Bismuth-213, Others

1 Study Coverage
1.1 Introduction to Targeted Alpha-particle Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Targeted Alpha-particle Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Actinium-225
1.2.3 Astatine-211
1.2.4 Lead-212
1.2.5 Bismuth-213
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Targeted Alpha-particle Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Immunotherapy
1.3.3 Peritoneal Carcinomas
1.3.4 Bone Metastases
1.3.5 Leukaemia
1.3.6 Melanomas
1.3.7 Solid Tumours
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Targeted Alpha-particle Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Targeted Alpha-particle Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Targeted Alpha-particle Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Targeted Alpha-particle Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Actinium-225 Market Size by Players
3.3.2 Astatine-211 Market Size by Players
3.3.3 Lead-212 Market Size by Players
3.3.4 Bismuth-213 Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Targeted Alpha-particle Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Targeted Alpha-particle Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Targeted Alpha-particle Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Targeted Alpha-particle Therapy Market Size by Type (2020-2031)
6.4 North America Targeted Alpha-particle Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Targeted Alpha-particle Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Targeted Alpha-particle Therapy Market Size by Type (2020-2031)
7.4 Europe Targeted Alpha-particle Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Targeted Alpha-particle Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Targeted Alpha-particle Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Targeted Alpha-particle Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Targeted Alpha-particle Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Targeted Alpha-particle Therapy Market Size by Type (2020-2031)
9.4 Central and South America Targeted Alpha-particle Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Targeted Alpha-particle Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Targeted Alpha-particle Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Targeted Alpha-particle Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Targeted Alpha-particle Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Business Overview
11.1.3 Bayer Targeted Alpha-particle Therapy Product Features and Attributes
11.1.4 Bayer Targeted Alpha-particle Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Bayer Targeted Alpha-particle Therapy Revenue by Product in 2024
11.1.6 Bayer Targeted Alpha-particle Therapy Revenue by Application in 2024
11.1.7 Bayer Targeted Alpha-particle Therapy Revenue by Geographic Area in 2024
11.1.8 Bayer Targeted Alpha-particle Therapy SWOT Analysis
11.1.9 Bayer Recent Developments
11.2 Orano Med
11.2.1 Orano Med Corporation Information
11.2.2 Orano Med Business Overview
11.2.3 Orano Med Targeted Alpha-particle Therapy Product Features and Attributes
11.2.4 Orano Med Targeted Alpha-particle Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Orano Med Targeted Alpha-particle Therapy Revenue by Product in 2024
11.2.6 Orano Med Targeted Alpha-particle Therapy Revenue by Application in 2024
11.2.7 Orano Med Targeted Alpha-particle Therapy Revenue by Geographic Area in 2024
11.2.8 Orano Med Targeted Alpha-particle Therapy SWOT Analysis
11.2.9 Orano Med Recent Developments
11.3 Oncoinvent AS
11.3.1 Oncoinvent AS Corporation Information
11.3.2 Oncoinvent AS Business Overview
11.3.3 Oncoinvent AS Targeted Alpha-particle Therapy Product Features and Attributes
11.3.4 Oncoinvent AS Targeted Alpha-particle Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Oncoinvent AS Targeted Alpha-particle Therapy Revenue by Product in 2024
11.3.6 Oncoinvent AS Targeted Alpha-particle Therapy Revenue by Application in 2024
11.3.7 Oncoinvent AS Targeted Alpha-particle Therapy Revenue by Geographic Area in 2024
11.3.8 Oncoinvent AS Targeted Alpha-particle Therapy SWOT Analysis
11.3.9 Oncoinvent AS Recent Developments
11.4 Perspective Therapeutics
11.4.1 Perspective Therapeutics Corporation Information
11.4.2 Perspective Therapeutics Business Overview
11.4.3 Perspective Therapeutics Targeted Alpha-particle Therapy Product Features and Attributes
11.4.4 Perspective Therapeutics Targeted Alpha-particle Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Perspective Therapeutics Targeted Alpha-particle Therapy Revenue by Product in 2024
11.4.6 Perspective Therapeutics Targeted Alpha-particle Therapy Revenue by Application in 2024
11.4.7 Perspective Therapeutics Targeted Alpha-particle Therapy Revenue by Geographic Area in 2024
11.4.8 Perspective Therapeutics Targeted Alpha-particle Therapy SWOT Analysis
11.4.9 Perspective Therapeutics Recent Developments
11.5 Ablaze Pharma
11.5.1 Ablaze Pharma Corporation Information
11.5.2 Ablaze Pharma Business Overview
11.5.3 Ablaze Pharma Targeted Alpha-particle Therapy Product Features and Attributes
11.5.4 Ablaze Pharma Targeted Alpha-particle Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Ablaze Pharma Targeted Alpha-particle Therapy Revenue by Product in 2024
11.5.6 Ablaze Pharma Targeted Alpha-particle Therapy Revenue by Application in 2024
11.5.7 Ablaze Pharma Targeted Alpha-particle Therapy Revenue by Geographic Area in 2024
11.5.8 Ablaze Pharma Targeted Alpha-particle Therapy SWOT Analysis
11.5.9 Ablaze Pharma Recent Developments
11.6 ARTBIO
11.6.1 ARTBIO Corporation Information
11.6.2 ARTBIO Business Overview
11.6.3 ARTBIO Targeted Alpha-particle Therapy Product Features and Attributes
11.6.4 ARTBIO Targeted Alpha-particle Therapy Revenue and Gross Margin (2020-2025)
11.6.5 ARTBIO Recent Developments
11.7 Fusion Pharmaceuticals(AstraZeneca)
11.7.1 Fusion Pharmaceuticals(AstraZeneca) Corporation Information
11.7.2 Fusion Pharmaceuticals(AstraZeneca) Business Overview
11.7.3 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product Features and Attributes
11.7.4 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Fusion Pharmaceuticals(AstraZeneca) Recent Developments
11.8 AlphaGen Therapeutics
11.8.1 AlphaGen Therapeutics Corporation Information
11.8.2 AlphaGen Therapeutics Business Overview
11.8.3 AlphaGen Therapeutics Targeted Alpha-particle Therapy Product Features and Attributes
11.8.4 AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue and Gross Margin (2020-2025)
11.8.5 AlphaGen Therapeutics Recent Developments
12 Targeted Alpha-particle TherapyIndustry Chain Analysis
12.1 Targeted Alpha-particle Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Targeted Alpha-particle Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Targeted Alpha-particle Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Bayer
Orano Med
Perspective Therapeutics
Oncoinvent AS
Ablaze Pharma
ARTBIO
Fusion Pharmaceuticals(AstraZeneca)
AlphaGen Therapeutics
List of Tables
 Table 1. Global Targeted Alpha-particle Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Targeted Alpha-particle Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Targeted Alpha-particle Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Targeted Alpha-particle Therapy Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Targeted Alpha-particle Therapy Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Targeted Alpha-particle Therapy Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Targeted Alpha-particle Therapy Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Targeted Alpha-particle Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Alpha-particle Therapy as of 2024)
 Table 11. Global Targeted Alpha-particle Therapy Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Targeted Alpha-particle Therapy Companies Headquarters
 Table 13. Global Targeted Alpha-particle Therapy Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Targeted Alpha-particle Therapy Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Targeted Alpha-particle Therapy Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Targeted Alpha-particle Therapy Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Targeted Alpha-particle Therapy Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Targeted Alpha-particle Therapy High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Targeted Alpha-particle Therapy Growth Accelerators and Market Barriers
 Table 25. North America Targeted Alpha-particle Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Targeted Alpha-particle Therapy Growth Accelerators and Market Barriers
 Table 27. Europe Targeted Alpha-particle Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Targeted Alpha-particle Therapy Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Targeted Alpha-particle Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Targeted Alpha-particle Therapy Investment Opportunities and Key Challenges
 Table 31. Central and South America Targeted Alpha-particle Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Targeted Alpha-particle Therapy Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Targeted Alpha-particle Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Bayer Corporation Information
 Table 35. Bayer Description and Major Businesses
 Table 36. Bayer Product Features and Attributes
 Table 37. Bayer Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Bayer Revenue Proportion by Product in 2024
 Table 39. Bayer Revenue Proportion by Application in 2024
 Table 40. Bayer Revenue Proportion by Geographic Area in 2024
 Table 41. Bayer Targeted Alpha-particle Therapy SWOT Analysis
 Table 42. Bayer Recent Developments
 Table 43. Orano Med Corporation Information
 Table 44. Orano Med Description and Major Businesses
 Table 45. Orano Med Product Features and Attributes
 Table 46. Orano Med Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Orano Med Revenue Proportion by Product in 2024
 Table 48. Orano Med Revenue Proportion by Application in 2024
 Table 49. Orano Med Revenue Proportion by Geographic Area in 2024
 Table 50. Orano Med Targeted Alpha-particle Therapy SWOT Analysis
 Table 51. Orano Med Recent Developments
 Table 52. Oncoinvent AS Corporation Information
 Table 53. Oncoinvent AS Description and Major Businesses
 Table 54. Oncoinvent AS Product Features and Attributes
 Table 55. Oncoinvent AS Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Oncoinvent AS Revenue Proportion by Product in 2024
 Table 57. Oncoinvent AS Revenue Proportion by Application in 2024
 Table 58. Oncoinvent AS Revenue Proportion by Geographic Area in 2024
 Table 59. Oncoinvent AS Targeted Alpha-particle Therapy SWOT Analysis
 Table 60. Oncoinvent AS Recent Developments
 Table 61. Perspective Therapeutics Corporation Information
 Table 62. Perspective Therapeutics Description and Major Businesses
 Table 63. Perspective Therapeutics Product Features and Attributes
 Table 64. Perspective Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Perspective Therapeutics Revenue Proportion by Product in 2024
 Table 66. Perspective Therapeutics Revenue Proportion by Application in 2024
 Table 67. Perspective Therapeutics Revenue Proportion by Geographic Area in 2024
 Table 68. Perspective Therapeutics Targeted Alpha-particle Therapy SWOT Analysis
 Table 69. Perspective Therapeutics Recent Developments
 Table 70. Ablaze Pharma Corporation Information
 Table 71. Ablaze Pharma Description and Major Businesses
 Table 72. Ablaze Pharma Product Features and Attributes
 Table 73. Ablaze Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Ablaze Pharma Revenue Proportion by Product in 2024
 Table 75. Ablaze Pharma Revenue Proportion by Application in 2024
 Table 76. Ablaze Pharma Revenue Proportion by Geographic Area in 2024
 Table 77. Ablaze Pharma Targeted Alpha-particle Therapy SWOT Analysis
 Table 78. Ablaze Pharma Recent Developments
 Table 79. ARTBIO Corporation Information
 Table 80. ARTBIO Description and Major Businesses
 Table 81. ARTBIO Product Features and Attributes
 Table 82. ARTBIO Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. ARTBIO Recent Developments
 Table 84. Fusion Pharmaceuticals(AstraZeneca) Corporation Information
 Table 85. Fusion Pharmaceuticals(AstraZeneca) Description and Major Businesses
 Table 86. Fusion Pharmaceuticals(AstraZeneca) Product Features and Attributes
 Table 87. Fusion Pharmaceuticals(AstraZeneca) Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Fusion Pharmaceuticals(AstraZeneca) Recent Developments
 Table 89. AlphaGen Therapeutics Corporation Information
 Table 90. AlphaGen Therapeutics Description and Major Businesses
 Table 91. AlphaGen Therapeutics Product Features and Attributes
 Table 92. AlphaGen Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. AlphaGen Therapeutics Recent Developments
 Table 94. Raw Materials Key Suppliers
 Table 95. Distributors List
 Table 96. Market Trends and Market Evolution
 Table 97. Market Drivers and Opportunities
 Table 98. Market Challenges, Risks, and Restraints
 Table 99. Research Programs/Design for This Report
 Table 100. Key Data Information from Secondary Sources
 Table 101. Key Data Information from Primary Sources


List of Figures
 Figure 1. Targeted Alpha-particle Therapy Product Picture
 Figure 2. Global Targeted Alpha-particle Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Actinium-225 Product Picture
 Figure 4. Astatine-211 Product Picture
 Figure 5. Lead-212 Product Picture
 Figure 6. Bismuth-213 Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Targeted Alpha-particle Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 9. Immunotherapy
 Figure 10. Peritoneal Carcinomas
 Figure 11. Bone Metastases
 Figure 12. Leukaemia
 Figure 13. Melanomas
 Figure 14. Solid Tumours
 Figure 15. Targeted Alpha-particle Therapy Report Years Considered
 Figure 16. Global Targeted Alpha-particle Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 18. Global Targeted Alpha-particle Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 19. Global Targeted Alpha-particle Therapy Revenue Market Share by Region (2020-2031)
 Figure 20. Global Targeted Alpha-particle Therapy Revenue Market Share Ranking (2024)
 Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 22. Actinium-225 Revenue Market Share by Player in 2024
 Figure 23. Astatine-211 Revenue Market Share by Player in 2024
 Figure 24. Lead-212 Revenue Market Share by Player in 2024
 Figure 25. Bismuth-213 Revenue Market Share by Player in 2024
 Figure 26. Others Revenue Market Share by Player in 2024
 Figure 27. Global Targeted Alpha-particle Therapy Revenue Market Share by Type (2020-2031)
 Figure 28. Global Targeted Alpha-particle Therapy Revenue Market Share by Application (2020-2031)
 Figure 29. North America Targeted Alpha-particle Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. North America Top 5 Players Targeted Alpha-particle Therapy Revenue (US$ Million) in 2024
 Figure 31. North America Targeted Alpha-particle Therapy Revenue (US$ Million) by Type (2020 - 2031)
 Figure 32. North America Targeted Alpha-particle Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 33. US Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 34. Canada Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 35. Mexico Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 36. Europe Targeted Alpha-particle Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 37. Europe Top 5 Players Targeted Alpha-particle Therapy Revenue (US$ Million) in 2024
 Figure 38. Europe Targeted Alpha-particle Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 39. Europe Targeted Alpha-particle Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 40. Germany Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 41. France Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 42. U.K. Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 43. Italy Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 44. Russia Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 45. Asia-Pacific Targeted Alpha-particle Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 46. Asia-Pacific Top 8 Players Targeted Alpha-particle Therapy Revenue (US$ Million) in 2024
 Figure 47. Asia-Pacific Targeted Alpha-particle Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 48. Asia-Pacific Targeted Alpha-particle Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 49. Indonesia Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 50. Japan Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 51. South Korea Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 52. Australia Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 53. India Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 54. Indonesia Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 55. Vietnam Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 56. Malaysia Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 57. Philippines Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 58. Singapore Targeted Alpha-particle Therapy Revenue (2020-2031) & (US$ Million)
 Figure 59. Central and South America Targeted Alpha-particle Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 60. Central and South America Top 5 Players Targeted Alpha-particle Therapy Revenue (US$ Million) in 2024
 Figure 61. Central and South America Targeted Alpha-particle Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 62. Central and South America Targeted Alpha-particle Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 63. Brazil Targeted Alpha-particle Therapy Revenue (2020-2025) & (US$ Million)
 Figure 64. Argentina Targeted Alpha-particle Therapy Revenue (2020-2025) & (US$ Million)
 Figure 65. Middle East and Africa Targeted Alpha-particle Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 66. Middle East and Africa Top 5 Players Targeted Alpha-particle Therapy Revenue (US$ Million) in 2024
 Figure 67. South America Targeted Alpha-particle Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 68. Middle East and Africa Targeted Alpha-particle Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 69. GCC Countries Targeted Alpha-particle Therapy Revenue (2020-2025) & (US$ Million)
 Figure 70. Israel Targeted Alpha-particle Therapy Revenue (2020-2025) & (US$ Million)
 Figure 71. Egypt Targeted Alpha-particle Therapy Revenue (2020-2025) & (US$ Million)
 Figure 72. South Africa Targeted Alpha-particle Therapy Revenue (2020-2025) & (US$ Million)
 Figure 73. Targeted Alpha-particle Therapy Industry Chain Mapping
 Figure 74. Channels of Distribution (Direct Vs Distribution)
 Figure 75. Bottom-up and Top-down Approaches for This Report
 Figure 76. Data Triangulation
 Figure 77. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Medical Alpha Radionuclide Market Research Report 2024
Global Targeted Radiotherapy Drug Market Research Report 2024
Global Targeted Radionuclide Therapy Market Research Report 2024
Global Radioimmunotherapy Market Research Report 2025
Global Targeted Radiopharmaceuticals Market Research Report 2024
Global Systemic Radiotherapy Market Research Report 2024
Global Alpha Emitters Market Research Report 2024
Global Therapeutic Radioligands Market Research Report 2024
Global Radioactive Therapeutic Drugs Market Research Report 2024
Global Oncology Targeted Therapy Market Research Report 2025
Global Cancer Targeted Drug Market Research Report 2025
Global Targeted Small Molecule Therapy Market Research Report 2025
Global Radiopharmaceutical Therapy Market Research Report 2025
Global Targeted Small Molecule Drug Market Research Report 2025
Radiopharmaceutical Theranostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cancer Targeted Small Molecule Therapy Market Research Report 2025
Global Antibody radionuclide Conjugates Market Research Report 2024
Global Targeted SSTR Radionuclide Drug Conjugates Market Research Report 2024
Global Heavy Ion Therapy Technology Market Research Report 2025
Global Cancer Particle Therapy Market Research Report 2024

RELATED REPORTS

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32T20006
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0Q20500
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-18V16958
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions